Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG106 plus Toripalimab in advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma
CTR20210031Phase 2Completed
- Sponsor
- Tianyan Pharmaceutical (Suzhou) Co., Ltd.
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ADG106, toripalimab in Nonhematologic neoplasms, non-Hodgkin lymphoma (NHL), sponsored by Tianyan Pharmaceutical (Suzhou) Co., Ltd.. Started Jan 2021; status: completed.
02
Drugs
ADG106toripalimab
03
Conditions
Nonhematologic neoplasmsnon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20210031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210031.